We are live on ! Find out more
EAM

Erste Asset Management Portfolio holdings

AUM $12.9B
1-Year Est. Return 52.69%
This Fund
S&P 500
This Quarter Est. Return
+8.41%
1 Year Est. Return
+52.69%
3 Year Est. Return
+142.55%
5 Year Est. Return
+182.36%
10 Year Est. Return
AUM
$5.55B
AUM Growth
+$502M
Cap. Flow
+$232M
Cap. Flow %
4.18%
Top 10 Hldgs %
19.68%
Holding
571
New
51
Increased
198
Reduced
144
Closed
33

Top Buys

Rank Stock Value
1
RUN icon
Sunrun
RUN
+$26.1M
2
CTAS icon
Cintas
CTAS
+$23.1M
3
NOVA
Sunnova Energy
NOVA
+$18.6M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$17.5M
5
DQ
Daqo New Energy
DQ
+$14M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$23.6M
2
SIMO icon
Silicon Motion
SIMO
+$20.7M
3
CMCSA icon
Comcast
CMCSA
+$17M
4
V icon
Visa
V
+$16.6M
5
TJX icon
TJX Companies
TJX
+$13.3M

Sector Composition

Rank Sector Weight
1 Technology 31.13%
2 Healthcare 18.96%
3 Consumer Discretionary 13.96%
4 Financials 9.3%
5 Industrials 7.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ICE icon
376
Intercontinental Exchange
ICE
$88.1B
$798K 0.01%
5,837
-305
-5% -$40.4K
HSY icon
377
Hershey
HSY
$34.2B
$794K 0.01%
4,156
+115
+3% +$20.8K
C icon
378
Citigroup
C
$228B
$759K 0.01%
12,533
+2,703
+27% +$180K
SWTX
379
DELISTED
SpringWorks Therapeutics
SWTX
$749K 0.01%
12,300
GE icon
380
GE Aerospace
GE
$319B
$735K 0.01%
12,454
+673
+6% +$42.3K
LNG icon
381
Cheniere Energy
LNG
$56B
$724K 0.01%
7,000
-2,300
-25% -$240K
HLNE icon
382
Hamilton Lane
HLNE
$5.13B
$716K 0.01%
6,857
+250
+4% +$25.7K
RVTY icon
383
Revvity
RVTY
$15.6B
$703K 0.01%
3,600
LGND icon
384
Ligand Pharmaceuticals
LGND
$5.52B
$700K 0.01%
6,893
RLAY icon
385
Relay Therapeutics
RLAY
$4.16B
$697K 0.01%
23,100
PNC icon
386
PNC Financial Services
PNC
$96.1B
$691K 0.01%
+3,433
New +$699K
ZLAB icon
387
Zai Lab
ZLAB
$2.78B
$690K 0.01%
10,900
CE icon
388
Celanese
CE
$5.18B
$685K 0.01%
4,100
+1,000
+32% +$163K
HIG icon
389
Hartford Financial Services
HIG
$36.8B
$675K 0.01%
9,700
-2,100
-18% -$148K
AUPH icon
390
Aurinia Pharmaceuticals
AUPH
$2.15B
$675K 0.01%
30,000
BEAM icon
391
Beam Therapeutics
BEAM
$2.4B
$672K 0.01%
8,500
-6,500
-43% -$557K
NKTR icon
392
Nektar Therapeutics
NKTR
$2.28B
$665K 0.01%
3,120
VCYT icon
393
Veracyte
VCYT
$3.23B
$664K 0.01%
17,000
FATE icon
394
Fate Therapeutics
FATE
$282M
$663K 0.01%
11,200
-6,000
-35% -$340K
GAP
395
The Gap Inc
GAP
$7.18B
$659K 0.01%
37,317
+15,900
+74% +$333K
AMRN
396
Amarin Corp
AMRN
$294M
$655K 0.01%
9,900
KMI icon
397
Kinder Morgan
KMI
$68.5B
$646K 0.01%
40,800
-10,000
-20% -$166K
OCUL icon
398
Ocular Therapeutix
OCUL
$2.24B
$632K 0.01%
95,800
ALLO icon
399
Allogene Therapeutics
ALLO
$594M
$626K 0.01%
40,800
BRO icon
400
Brown & Brown
BRO
$22.5B
$621K 0.01%
8,900

Similar funds

Erste Asset Management's Q4 2021 Portfolio in Review

As of Q4 2021, Erste Asset Management held 571 positions worth $5.55B, up 9.9% from $5.05B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Erste Asset Management deployed $232M of net new capital in Q4 2021, opening 51 new positions and adding to 198 existing holdings. Its largest new stake was Cintas: 214,128 shares worth $23.7M.

By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was NVIDIA, an estimated $23.6M trimmed.

  • Erste Asset Management's largest Q4 2021 buy was Cintas: 214,128 shares worth $23.7M.
  • Erste Asset Management added most to Sunrun in Q4 2021, an estimated $26.1M increase.
  • Erste Asset Management's biggest Q4 2021 reduction was NVIDIA, cutting an estimated $23.6M.
  • Erste Asset Management fully exited Advanced Energy in Q4 2021, selling an estimated $8M.
  • Erste Asset Management's ten largest holdings make up 20% of its $5.55B portfolio in Q4 2021.
  • Erste Asset Management opened 51 new positions and closed 33 in Q4 2021.
  • Erste Asset Management's portfolio value rose 9.9% quarter-over-quarter to $5.55B.

Based on Erste Asset Management's 13F filing for Q4 2021, filed 25 Nov 2024.